Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation
- PMID: 12684900
- DOI: 10.1007/s00431-003-1188-9
Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation
Abstract
This paper presents data obtained by questionnaires sent to local hospitals and metabolic centres in Germany, Austria, Italy and Switzerland concerning the survival and outcome of patients with urea cycle disorders treated between 1975 and 1986. A total of 130 questionnaires were sent out of which 88 questionnaires of patients were returned. This study compares results of conservative long-term management using protein restriction versus protein restriction combined with more extensive treatment (arginine/citrulline, essential amino acid supplements and sodium benzoate as alternate pathway therapy). While survival was improved in neonates receiving extensive therapy, there was an increased risk of mental retardation on long-term follow-up in this group. The time at which the first symptoms of hyperammonaemia appeared, the age at diagnosis, and the time of delay in diagnosis after the first symptom were not helpful in predicting outcome; however, when plasma ammonia concentrations exceeded 300 micromol/l initially or 480 micromol/l at its peak, none of the patients had a normal cognitive outcome.
Conclusion: there is a need to establish improved treatment approaches and a network of "rare disease" centres to assure the rapid diagnosis and effective treatment and follow-up of affected children. This should precede any consideration of neonatal screening for urea cycle disorders.
Similar articles
-
Long-term outcome of patients with urea cycle disorders and the question of neonatal screening.Eur J Pediatr. 2003 Dec;162 Suppl 1:S29-33. doi: 10.1007/s00431-003-1347-z. Epub 2003 Nov 21. Eur J Pediatr. 2003. PMID: 14634803
-
Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.N Engl J Med. 2007 May 31;356(22):2282-92. doi: 10.1056/NEJMoa066596. N Engl J Med. 2007. PMID: 17538087 Clinical Trial.
-
Urea cycle disorders.Semin Neonatol. 2002 Feb;7(1):27-35. doi: 10.1053/siny.2001.0085. Semin Neonatol. 2002. PMID: 12069536 Review.
-
Incidence, disease onset and short-term outcome in urea cycle disorders -cross-border surveillance in Germany, Austria and Switzerland.Orphanet J Rare Dis. 2017 Jun 15;12(1):111. doi: 10.1186/s13023-017-0661-x. Orphanet J Rare Dis. 2017. PMID: 28619060 Free PMC article.
-
Ammonia toxicity and its prevention in inherited defects of the urea cycle.Diabetes Obes Metab. 2009 Sep;11(9):823-35. doi: 10.1111/j.1463-1326.2009.01054.x. Epub 2009 Jun 16. Diabetes Obes Metab. 2009. PMID: 19531057 Review.
Cited by
-
Citrullinemia, a rare cause of recurring encephalopathy.Med J Armed Forces India. 2022 Sep;78(Suppl 1):S319-S322. doi: 10.1016/j.mjafi.2019.12.007. Epub 2020 Mar 19. Med J Armed Forces India. 2022. PMID: 36147420 Free PMC article.
-
Therapeutic effect of N-carbamylglutamate in CPS1 deficiency.Mol Genet Metab Rep. 2020 Jul 8;24:100622. doi: 10.1016/j.ymgmr.2020.100622. eCollection 2020 Sep. Mol Genet Metab Rep. 2020. PMID: 32670798 Free PMC article.
-
S100B Protein but Not 3-Nitrotyrosine Positively Correlates with Plasma Ammonia in Patients with Inherited Hyperammonemias: A New Promising Diagnostic Tool?J Clin Med. 2023 Mar 21;12(6):2411. doi: 10.3390/jcm12062411. J Clin Med. 2023. PMID: 36983411 Free PMC article.
-
Continuous renal replacement therapy and therapeutic plasma exchange in pediatric liver failure.Eur J Pediatr. 2024 Aug;183(8):3289-3297. doi: 10.1007/s00431-024-05587-3. Epub 2024 May 8. Eur J Pediatr. 2024. PMID: 38717620
-
Clinical practice: the management of hyperammonemia.Eur J Pediatr. 2011 Jan;170(1):21-34. doi: 10.1007/s00431-010-1369-2. Epub 2010 Dec 17. Eur J Pediatr. 2011. PMID: 21165747 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical